Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck (MRK) beats Q3 estimates for earnings and sales. The company continues to see robust growth in Keytruda and Gardasil sales.

Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View

Merck & Co., Inc. (NYSE:MRK ) Q3 2022 Earnings Conference Call October 27, 2022 8:00 AM ET Company Participants Peter Dannenbaum - Vice President, Investor Relations Rob Davis - President and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dean Li - President, Merck Research Labs Conference Call Participants Chris Schott - JP Morgan Daina Graybosch - SVB Securities Colin Bristow - UBS Seamus Fernandez - Guggenheim Steve Scala - Cowen Mara Goldstein - Mizuho Umer Raffat - Evercore Mohit Bansal - Wells Fargo Chris Shibutani - Goldman Sachs Luisa Hector - Berenberg Operator Ladies and gentlemen, thank you for standing by. Good morning.

Merck & Co., Inc. (MRK) Q3 2022 Earnings Call Transcript

Is Merck stock a buy after the company notched a third-quarter beat and raised guidance for 2022? Is MRK stock a buy now?

Merck Stock Hits A Fresh High After Third-Quarter Beat, But Is It A Buy?

Merck (MRK) delivered earnings and revenue surprises of 10.78% and 6.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Q3 Earnings and Revenues Surpass Estimates

Merck stock jumped Thursday after the company beat third-quarter forecasts and raised its full-year guidance despite exchange-rate struggles. The post Merck Outmaneuvers Exchange-Rate Headwinds For A Bullish Beat-And-Raise appeared first on Investor's Business Daily.

Merck Outmaneuvers Exchange-Rate Headwinds For A Bullish Beat-And-Raise

Shares of Merck & Co. Inc. MRK, +0.72% rose 1.4% in premarket trading Thursday, after the drug giant reported third-quarter profit and sale that beat expectations and raised its full-year outlook, as sales of the company's top 3 selling drugs topped forecasts. Net income fell to $3.25 billion, or $1.28 a share, from $4.57 billion, or $1.80 a share, in the year-ago period.

Merck stock rises after profit and sales beat, raised outlook

Merck Announces Third-Quarter 2022 Financial Results

Longtime Chairman Ken Frazier plans to leave Merck's board, handing the job to his successor as chief executive, Rob Davis.

Merck Shuffles Board Chairmen

Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck

Merck will soon share its positive phase 3 clinical trial results for a rare disease drug candidate at an upcoming event.

Is Merck Moving Toward Another Blockbuster Drug Launch?

DeepMatter Group PLC (AIM:DMTR), the digital chemistry data and software company, announced a multi-year database licence agreement with Merck & Co Inc (NYSE:MRK) and forecast strong revenue growth for the current financial year.  Under the deal, DeepMatter will license certain proprietary data for machine learning-based applications to Merck's life science business.

DeepMatter sees 50% growth in full-year revenue and inks multi-year licence deal with Merck

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced it will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held October 26-28, 2022 in Amsterdam, the Netherlands.

Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

Merck's top-selling drug - Keytruda - saw its sales rise 26% to $5.3 billion in Q2, while Gardasil sales were up a significant 36% to $1.7 billion.

Will Merck Stock Rise After Its Q3 Results?

Merck has proven to be a resilient healthcare business that has provided growth, while the share price hasn't moved all that much. This year that has changed, and Merck shares are rising above peers with positive returns YTD.

Merck: A Shield From Recession

Selling this spread would generate roughly $90 in premium, which would be a 22% return in around three and a half weeks. The post Merck Offers Potential 22% Return For Bullish Option Traders appeared first on Investor's Business Daily.

Merck Offers Potential 22% Return For Bullish Option Traders

Cigna

Chevron

Lockheed Martin

SentinelOne

Unity Software

I'm generally the positive type. Still, as I look at the market, the math isn't on my side.

7 Stocks to Sell Before They Give Back This Year's Gain

Apple

First Solar

Stepan

Texas Instruments

Worthington Industries

Investors active in ESG investing consider a company's corporate values and environmental practices. But they're also seeking to buy the best ESG stocks, those that make solid returns.

IBD's Three Best ESG Companies In Eight Industry Categories For 2022

European Commission Expands Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents

Eli Lilly

This is likely the last bearish week before a rally runs through the next two months.

Stocks This Week: Buy Merck And Eli Lilly

Merck's PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation

Merck stock has been showing relative strength ahead of its Q3 earnings report. Results are due Oct. 27 before the opening bell.

Merck Stock In Bullish Setup Ahead Of Q3 Results; Apple Leads FAANG Earnings Barrage

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline

Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.

Merck Nears Breakout Point After October Surprise Good News

Drugmaker Merck said on Wednesday that it had been placed under formal investigation by a French court for possibly issuing misleading information regarding its thyroid drug product Levothyrox.

Drugmaker Merck: placed under formal investigation in France over Levothyrox

New smart device provides geolocation and dog behavioral tracking capabilities MADISON, N.J. , Oct. 18, 2022 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co, Inc., Rahway, N.J.

News for Merck Stock (MRK)